A detailed history of Exodus Point Capital Management, LP transactions in G1 Therapeutics, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 19,747 shares of GTHX stock, worth $48,380. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,747
Holding current value
$48,380
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$2.1 - $4.83 $41,468 - $95,378
19,747 New
19,747 $85,000
Q4 2022

Feb 13, 2023

SELL
$5.19 - $13.5 $337,775 - $878,607
-65,082 Reduced 82.45%
13,856 $75,000
Q3 2022

Nov 10, 2022

BUY
$5.17 - $16.99 $350,887 - $1.15 Million
67,870 Added 613.21%
78,938 $986,000
Q2 2022

Aug 19, 2022

SELL
$4.04 - $8.51 $61,161 - $128,832
-15,139 Reduced 57.77%
11,068 $55,000
Q1 2022

May 13, 2022

BUY
$7.6 - $11.02 $31,920 - $46,284
4,200 Added 19.08%
26,207 $199,000
Q4 2021

Feb 11, 2022

SELL
$10.16 - $16.17 $133,776 - $212,910
-13,167 Reduced 37.43%
22,007 $225,000
Q3 2021

Nov 15, 2021

BUY
$13.16 - $22.47 $462,889 - $790,359
35,174 New
35,174 $472,000
Q1 2021

May 17, 2021

SELL
$17.58 - $32.59 $519,752 - $963,523
-29,565 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$10.99 - $20.4 $180,203 - $334,498
-16,397 Reduced 35.68%
29,565 $532,000
Q3 2020

Nov 16, 2020

BUY
$11.55 - $23.75 $139,466 - $286,781
12,075 Added 35.63%
45,962 $531,000
Q2 2020

Aug 14, 2020

BUY
$9.57 - $24.37 $324,298 - $825,826
33,887 New
33,887 $822,000
Q4 2019

Feb 14, 2020

SELL
$20.54 - $31.0 $187,879 - $283,557
-9,147 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$22.78 - $40.58 $208,368 - $371,185
9,147 New
9,147 $208,000

Others Institutions Holding GTHX

About G1 Therapeutics, Inc.


  • Ticker GTHX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,746,800
  • Market Cap $105M
  • Description
  • G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/...
More about GTHX
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.